adbchminaca also known mabchminaca indazolebased synthetic cannabinoid potent agonist receptor binding affinity ki nm originally developed pfizer analgesic identified cannabinoid blends japan early number reported cases deaths hospitalizations relation synthetic united states adbchminaca schedule controlled prior listing federal level louisiana placed adbchminaca schedule list emergency scheduling swedens public health agency suggested classify adbchminaca hazardous substance november adbchminaca listed fifth schedule misuse drugs act mda therefore illegal singapore may adbchminaca illegal switzerland december ten adbchminaca major metabolites identified several incubations cryopreserved human hepatocytes transformations occurred cyclohexylmethyl tail httpsenwikipediaorgwikiadbchminaca